abrdn plc Has $2.69 Million Stake in TScan Therapeutics, Inc. (NASDAQ:TCRX)

abrdn plc increased its holdings in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) by 137.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 883,704 shares of the company's stock after buying an additional 512,049 shares during the quarter. abrdn plc owned 1.66% of TScan Therapeutics worth $2,686,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of TCRX. China Universal Asset Management Co. Ltd. acquired a new position in shares of TScan Therapeutics in the 4th quarter valued at approximately $32,000. Heck Capital Advisors LLC bought a new position in TScan Therapeutics in the fourth quarter valued at approximately $61,000. SG Americas Securities LLC boosted its holdings in shares of TScan Therapeutics by 31.2% in the fourth quarter. SG Americas Securities LLC now owns 20,415 shares of the company's stock valued at $62,000 after buying an additional 4,852 shares during the period. Dimensional Fund Advisors LP bought a new stake in shares of TScan Therapeutics during the second quarter worth $70,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of TScan Therapeutics during the second quarter worth $90,000. Institutional investors and hedge funds own 82.83% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on TCRX. Needham & Company LLC reaffirmed a "buy" rating and set a $11.00 price objective on shares of TScan Therapeutics in a research report on Wednesday, December 11th. HC Wainwright reaffirmed a "buy" rating and set a $15.00 price target on shares of TScan Therapeutics in a research report on Wednesday, December 11th. Finally, Wedbush reiterated an "outperform" rating and issued a $7.00 price objective on shares of TScan Therapeutics in a report on Monday, December 23rd.

TScan Therapeutics Stock Down 3.3 %

Shares of NASDAQ:TCRX traded down $0.07 during trading on Thursday, hitting $2.04. 318,373 shares of the company were exchanged, compared to its average volume of 281,020. TScan Therapeutics, Inc. has a fifty-two week low of $2.02 and a fifty-two week high of $9.69. The stock has a market cap of $108.87 million, a price-to-earnings ratio of -1.92 and a beta of 0.87. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.13. The firm has a fifty day moving average price of $2.78 and a two-hundred day moving average price of $4.48.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.25) earnings per share for the quarter, topping analysts' consensus estimates of ($0.28) by $0.03. The business had revenue of $1.05 million for the quarter, compared to the consensus estimate of $2.86 million. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. As a group, research analysts anticipate that TScan Therapeutics, Inc. will post -1.12 earnings per share for the current fiscal year.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.